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A B S T R A C T
The precursor lesion of vulvar squamous cell carcinoma (VSCC), namely vulvar intraepithelial neoplasia (VIN), is
classified as: human papillomavirus (HPV)-related high grade squamous intraepithelial lesion (HSIL), and HPV-
independent differentiated VIN (dVIN). Traditionally, histology and immunohistochemistry (IHC) have been the
basis of diagnosis and classification of VIN. HSIL shows conspicuous histological atypia, and positivity on p16-
IHC, whereas dVIN shows less obvious histological atypia, and overexpression or null-pattern on p53-IHC. For
both types of VIN, other diagnostic immunohistochemical markers have also been evaluated. Molecular char-
acterization of VIN has been attempted in few recent studies, and novel genotypic subtypes of HPV-independent
VSCC and VIN have been identified.
This systematic review appraises the VSCC precursors identified so far, focusing on histology and biomarkers
(immunohistochemical and molecular). To gain further insights into the carcinogenesis and to identify addi-
tional potential biomarkers, gene expression omnibus (GEO) datasets on VSCC were analyzed; the results are
presented.
1. Introduction
Vulvar squamous cell carcinoma (VSCC) constitutes 90% of all
vulvar malignancies, and arises from the precursor lesion, vulvar in-
traepithelial neoplasia (VIN) (WHO, 2014). Around 1/3rd of VSCC are
caused by human papillomavirus (HPV), and the precursor lesion for
this group is usual VIN/high grade squamous intraepithelial lesion
(uVIN/HSIL) (WHO, 2014; Bornstein, 2016). The majority of VSCC are,
however, HPV-independent and arise on the background of chronic
dermatoses. Somatic mutations of TP53 have been implicated in the
pathogenesis of this category, and the precursor lesion is called differ-
entiated VIN (dVIN) (WHO, 2014; Bornstein, 2016).
Traditionally, histology and immunohistochemistry (IHC) have
been the basis of diagnosis and classification of VIN and VSCC. In recent
years, for several cancers, advanced molecular analyses have allowed
more objective classification, and identification of diagnostic and
prognostic biomarkers. For VIN and VSCC, molecular characterization
has been attempted in a limited number of studies so far.
This systematic review was performed with the objective of ap-
praising the histological features of, and the biomarkers (im-
munohistochemical and molecular) for VSCC precursors. To gain fur-
ther insights into VSCC carcinogenesis, publicly available datasets on
expression profiling of VSCC were analyzed; these results are also
presented.
2. Materials and methods
2.1. Literature review
The recommendations of the Preferred Reporting Items for
Systematic Reviews and Meta-analysis (PRISMA) protocol were fol-
lowed (Anon, 2019a). The review was registered in the International
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T
Prospective Register of Systematic Reviews (PROSPERO), with acces-
sion number CRD42019107290 (Anon, 2019b).
Electronic search strategies combining Medical Subject Headings
(MeSH) and free-text words were prepared, with the help of medical
librarians at Erasmus MC. Biomedical bibliographic databases, viz.
Embase.com, MEDLINE Epub (Ovid), Cochrane Central Register for
Controlled Trials (CENTRAL), Web of Science (Science and Social
Science Citation Index), were searched. The full search strategy is
provided in supplementary document 1. Date restriction was not ap-
plied. The last search was conducted in May 2019. Citation, reference,
and hand searching were additionally performed.
Original articles and review articles describing either the histology,
or immunohistochemical or molecular markers of VSCC precursors, and
written in English were included. Case reports, conference abstracts,
animal studies, and in-vitro studies were excluded.
A total of 1112 references were retrieved, of which 373 were in-
cluded after the first round of screening by one author (SDG). These 373
references were independently screened by three other authors (PEG,
SK, and FvK) by reading the titles. PEG, SK, and FvK are practising
pathologists with substantial experience in the subject content. One
hundred and fifty four references met consensus for inclusion; full text
was available for 127 of these. Nine additional references were iden-
tified through reference searches. The final inclusion constituted 106
articles (99 original articles, 7 reviews). The process of reference se-
lection is delineated in Fig. 1.
Due to variability in the nomenclature, and heterogeneity in the
published data, a meta-analysis could not be performed, and a narrative
synthesis was prepared.
2.2. Gene expression omnibus (GEO) DataSet analysis
Datasets on gene expression analyses of VSCC were searched on
GEO. Four datasets were identified, of which 3 were discarded; 2 owing
to very low number of samples, and 1 due to lack of intensity values.
The included dataset (GSE38228) contained gene expression data from
14 VSCC and 5 normal vulvar samples, performed on Illumina Human
HT-12 V4.0 (Micci et al., 2013). The signal intensity data had been 2log
transformed (base2) and quantile normalised (Bolstad et al., 2003).
The data was imported into OmniViz (version 6.1.13.0, BioWisdom
Ltd., Cambridge, UK) for further analysis. For each probe set, the geo-
metric mean of the hybridization intensity of all samples was calcu-
lated, and the level of expression was assessed relative to this geometric
mean and 2log-transformed. The geometric mean of the hybridization
signal of all samples was used to ascribe equal weight to gene expres-
sion levels with similar relative distances to the geometric mean.
Differentially expressed genes between VSCC and controls were iden-
tified using statistical analysis of microarrays (SAM). Cutoff values for
significantly expressed genes were a false discovery rate (FDR) of ≤
0.01, and a fold change of 1.5. Functional annotation of the SAM results
was done using Ingenuity Pathway Analysis (IPA, QIAGEN, Mountain
View, CA), and Database for Annotation, Visualization and Integrated
Discovery (DAVID, version 6.8, NIAID/NIH).
3. Results
The information extracted from the literature, and the results of
GEO analyses were categorised as pertaining to HPV-related VSCC
precursors, or HPV-independent VSCC precursors, and are presented in
the subsequent sections. The evolution of terminology, etiopathogen-
esis, and clinical features for both categories, extracted from the in-
cluded literature, are also briefly discussed.
3.1. Evolution of terminology
The term intraepithelial neoplasia was introduced in 1967, and was
adopted by the International Society for the Study of VulvoVaginal
Diseases (ISSVD) in 1986 (Crum et al., 1982; Wilkinson et al., 1986).
Initially, a three-tier grading system for VIN (VIN I, II, III) was re-
commended. The VINI category was later removed, as this almost never
progressed to VSCC (Sideri et al., 2005). In 2004, the ISSVD scheme was
modified to include usual VIN (uVIN), and differentiated VIN (dVIN), to
signify HPV-related and HPV-independent VSCC precursors respec-
tively (Sideri et al., 2005).
With a view to achieving uniformity in terminology, in 2012, the
Lower Anogenital Squamous Terminology (LAST) committee re-
commended the terminology of squamous intraepithelial lesion (SIL)
for VSCC precursors, classified as low grade SIL (LSIL) and high grade
SIL (HSIL) (Darragh et al., 2012). The 2014 World Health Organization
(WHO), and 2015 ISSVD classifications accepted the SIL terminology
for HPV-related VIN, and retained dVIN as a separate category (WHO,
2014; Bornstein, 2016). In this review, we used HSIL, and dVIN to refer
to the precursors of HPV-related VSCC and HPV-independent VSCC
respectively.
3.2. HPV-related VSCC precursors (HSIL)
3.2.1. Etiopathogenesis
More than 80% of HSIL have been reported to be HPV-positive,
frequently detected genotypes being high-risk HPV16 (77.2%), HPV33
(10.6%), and HPV18 (2.6%) (van de Nieuwenhof et al., 2008; Scurry
et al., 2006; Medeiros et al., 2005; van Beurden et al., 1995; Bonvicini
et al., 2005; Bornstein et al., 1988; Buscema et al., 1988; Haefner et al.,
1995; Park et al., 1991).
Similar high rates of HPV-positivity, however, have not been found
in VSCC. Only 28.6% of cases from an international cohort of 1709
VSCC were found to harbor HPV, in 75% of which, HPV16 was detected
(de Sanjosé et al., 1990). Other studies have reported 15–79% HPV-
positivity in VSCC (del Pino et al., 2013). Low-risk HPV6 and HPV11
have been infrequently reported in VSCC; their exact role in the car-
cinogenesis is unclear (Iwasawa et al., 1997; Hampl et al., 2007).
High-risk HPV mediates carcinogenesis primarily through the on-
coproteins E6 and E7; these interfere with the functioning of tumor
suppressor retinoblastoma protein (pRB), and p53 (Lerma et al., 2002).
Loss of pRB generates oncogenic stress, potentially leading to p16INK4a
over-expression, and thus allowing hyper-proliferation of the infected
cells (Lerma et al., 2002; Riethdorf et al., 2004).
To facilitate carcinogenesis, persistent HPV-infection also induces a
local immunosuppressive microenvironment, characterized by reduced
concentrations of (CD1a+ and CD207+) dendritic cells and HPV-spe-
cific (CD4+ and CD8+) T-cells, and upregulation of T-regulatory cells
(Santegoets et al., 2008; Preti et al., 2014; Terlou et al., 2010). Treat-
ment with imiquimod is known to normalize (CD4+, CD8+) T-cell
counts in the epidermis, and bring about viral clearance (Terlou et al.,
2010).
3.2.2. Clinical features
HSIL most commonly affects women of 40–44 years, with a second
peak after 55 years (van Beurden et al., 1995; de Sanjosé et al., 1990;
Terlou et al., 2010; Jones et al., 2005). Patients commonly present with
pain, pruritus, or dysuria, although 40% can be asymptomatic (Al-
Ghamdi et al., 2002). Clinically, these lesions can be whitish, er-
ythematous, or pigmented macules, papules, or verrucous plaques (van
Beurden et al., 1995; McNally et al., 2002; Chafe et al., 1988; van Seters
et al., 2005). HSIL can be multifocal in 70% of cases, and the com-
monest locations are the labia minora and perineum (Al-Ghamdi et al.,
2002; Chafe et al., 1988; van Seters et al., 2005). Due to the ‘field effect’
induced by HPV, patients with HSIL may have concurrent involvement
of other ano-genital sites (Preti et al., 2014; Jones et al., 2005; McNally
et al., 2002; Chafe et al., 1988; van Seters et al., 2005; Léonard et al.,
2014; van der Avoort et al., 2006). A thorough examination of the
entire lower genital tract is therefore recommended for all HSIL pa-
tients.
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HSIL has a relatively low risk of progression to VSCC: 9–16% for
untreated cases, and 3% for treated cases. Around 1.2% of HSIL spon-
taneously regress (Jones et al., 2005; McNally et al., 2002; Léonard
et al., 2014; Sykes et al., 2002). The reported recurrence rate for HSIL
varies between 13–36% (Preti et al., 2014; McNally et al., 2002; Sykes
et al., 2002; Preti et al., 2015).
3.2.3. Histological features
Histological features of HSIL were extracted from 9 studies (Preti
et al., 2014; Knight, 1943; Baggish et al., 1989; Shatz et al., 1989; Hart,
2001; Scurry and Wilkinson, 2006; Hoang et al., 2016; Cohen et al.,
2019; Rakislova et al., 2018). The architectural and cytological ab-
normalities of HSIL are conspicuous, and often apparent under low
magnification [Fig. 2]. A basophilic (basaloid) appearance can fre-
quently be appreciated in HSIL (Cohen et al., 2019). The key identifying
features include high nuclear-to-cytoplasmic ratio, hyperchromasia,
pleomorphism, multinucleated cells, mitoses, and apoptotic bodies
[Fig. 2] (Hoang et al., 2016). The disturbed orientation of the dysplastic
epithelial cells often render a ‘wind-blown’ appearance to HSIL (Hoang
et al., 2016). Tangential sectioning of HSIL with extensive down-
growths, or with involvement of skin appendages, can mimic early in-
vasion and these should be interpreted with caution (Baggish et al.,
1989; Shatz et al., 1989; Hart, 2001). The histological features are listed
in Table 1.
Two histological variants of HSIL have been reported: warty/con-
dylomatous, and basaloid/undifferentiated (Hoang et al., 2016). Warty
HSIL has an acanthotic or papillary surface, with deep and wide rete
ridges, abundant koilocytes, and dyskeratotic cells (Scurry and
Wilkinson, 2006; Hoang et al., 2016). Basaloid HSIL is flat, with small,
uniform, basaloid cells often replacing the entire epithelium (Scurry
and Wilkinson, 2006; Hoang et al., 2016). Since some HSIL exhibit
histological features from both variants, it has been assumed that these
are a part of the same spectrum.
HSIL can also histologically mimic dVIN, with a pooled prevalence
of 2% (Cohen et al., 2019; Rakislova et al., 2018; Faber et al., 2017).
Similarly to dVIN, these show cytoplasmic eosinophilia due to ab-
normal keratinization, spongiosis, and atypia limited to the basal and
parabasal layers (Rakislova et al., 2018). Rakislova et al. demonstrated
p16-positivity, and detected HPV16 in these dVIN-like HSIL (Rakislova
et al., 2018). HSIL with superimposed lichen simplex chronicus (LSC)
Fig. 1. PRISMA flow diagram depicting the process of reference selection.
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can also mimic dVIN histologically, but can be correctly diagnosed
through p16-positivity on IHC (Watkins et al., 2019).
3.2.4. Immunohistochemical markers
Immunohistochemical markers studied in HSIL are presented below,
and summarized in Table 2. This information was extracted from 24
studies (Lerma et al., 2002; Riethdorf et al., 2004; van der Avoort et al.,
2006; Rakislova et al., 2018; Watkins et al., 2019; Yang and Hart, 2020;
Dong et al., 2015; Cheng et al., 2015; Hoevenaars et al., 2008; Jeffreys
et al., 2018; Rolfe et al., 2001; Samartzis et al., 2011; Li et al., 2013;
Brustmann and Brunner, 2013; Brustmann et al., 2011; Goyal et al.,
2018; Chen et al., 2010; Wellenhofer and Brustmann, 2012; Pinto et al.,
2013; Nooij et al., 2016; Stewart and Crook, 2014; Podoll et al., 2016;
Ekeowa-Anderson et al., 2012; Bovo et al., 2004). The im-
munohistochemical markers have been categorized as per their sub-
cellular location as nuclear, cytoplasmic, or extra-cellular. The biolo-
gical processes and canonical pathways associated with these markers
are presented in Table S1(supplementary document 2).
3.2.4.1. Nuclear markers
(i) p16: As per LAST guidelines, continuous/diffuse/band-like/block-
like strong nuclear, or nuclear with cytoplasmic p16-expression in
the basal layer, extending up to at least one-third of the epithelial
thickness, is to be interpreted as ‘positive’ p16-staining [Fig. 3]
(Darragh et al., 2012). Cytoplasmic staining alone, or patchy focal
staining without staining in the basal layers should be interpreted as
p16-negative.
Positivity with p16-IHC has been reported for stand-alone HSIL, as
well as HSIL adjacent to VSCC (Lerma et al., 2002; Rakislova et al.,
2018; Watkins et al., 2019; Yang and Hart, 2020; Dong et al., 2015;
Cheng et al., 2015; Hoevenaars et al., 2008; Jeffreys et al., 2018). With
p16-IHC, improvement in the inter-observer agreement in HSIL
Fig. 2. High grade squamous intraepithelial lesion (HSIL) with characteristic
histological features; hematoxylin-eosin (HE) stain. A. Acanthosis with club
shaped rete ridges, and a basophilic appearance of the epithelium can be ap-
preciated under low magnification (original magnification 25X). B. Cellular
crowding, anisonucleosis, pleomorphic cells with high nuclear cytoplasmic
ratio (arrow), hyperkeratosis and parakeratosis (asterisk) can be observed
under higher magnification (original magnification 100X).
Table 1
Histological features of HSIL, and dVIN
Histological features of HSIL
Knight (1943)
1 Hyperkeratosis
2 Parakeratosis
3 Acanthosis with club shaped rete ridges
4 Disorientation of the individual cells commencing
above the basal cell layer with variable extension to
the surface
5 Nuclear clumping with mitotic figures
6 Intact basement membrane
Other literature (Preti et al., 2014; Knight, 2020; Baggish et al., 1989; Shatz
et al., 1989; Hart, 2001; Scurry and Wilkinson, 2006; Hoang et al., 2016;
Cohen et al., 2019; Rakislova et al., 2018)
1 High nuclear-cytoplasmic ratio
2 Hyperchromasia
3 Pleomorphism
4 Multinucleated cells
5 Mitoses
6 Apoptotic bodies
WHO 2014 criteria (WHO, 2014)
1
1
1
1 Epithelial cell hyperchromasia
2 Cellular crowding
3 Anisonucleosis
4 Acanthosis
5 Parakeratosis
6 Hyperkeratosis
7 Variable HPV cytopathic effect
Histological features of dVIN
Yang and Hart (Yang and Hart (2020))
1 Variable nuclear atypia, from slight-to-moderate
degree, to occasionally severe
2 Hyperchromatic nuclei with irregular contours in the
basilar cells
3 Vesicular nuclei
4 Macronucleoli
5 Binucleated cells
6 Scattered mitoses, in basilar and suprabasilar layers
7 Enlarged cells
8 Elongated and frequently branched rete ridges
9 Abundant, brightly eosinophilic cytoplasm
10 Prominent intercellular bridges
11 Whorls of differentiated cells, with/without keratin
pearls
Other literature
(Preti et al., 2014; Hart, 2001; Hoang et al., 2016; Cohen et al., 2019; Bigby
et al., 2016; Reutter et al., 2016; van den Einden et al., 2013; Dasgupta et al.,
2018; Singh et al., 2015; Ordi et al., 2009)
1 Basal cellular atypia (including disarray of the basal cellular layers, large
pleomorphic keratinocytes)
2 Angulated nuclei
3 Atypical mitosis in the basal layer
4 Mitotic count > 5 / 5mm
5 Prominent nucleoli/Macronucleoli
6 Individual cell keratinisation
7 Deep keratinisation
8 Deep squamous eddies
9 Cobblestone appearance
10 Hypermaturation of rete ridges
11 Elongation and anastomosis of rete ridges
12 Hyperplasia/Acanthosis
13 Hyperkeratosis
14 Parakeratosis
WHO 2014 criteria (WHO, 2014)
1 Basal cell atypia, with nuclear
hyperchromasia
2 Karyomegaly
3 Prominent nucleoli
4 Atypical mitoses in the basal layer
5 Dyskeratosis
6 Individual cell keratosis
7 Elongation and anastomosis of rete
ridges
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diagnosis has been reported (Darragh et al., 2012).
The combination of positive HPV-polymerase chain reaction (HPV-
PCR), and block-positive p16-IHC is considered to be the ‘gold standard’
for diagnosing HSIL (Cohen et al., 2019). However, p16-IHC alone is
considered a reliable surrogate marker for HPV-infection (Riethdorf
et al., 2004; Yang and Hart, 2020; Dong et al., 2015; Cheng et al., 2015;
Hoevenaars et al., 2008). p16-IHC can also help distinguish HSIL from
benign mimics, such as transition zone mucosa, squamous hyperplasia,
or radiation change, which are p16-negative (Darragh et al., 2012).
Table 2
Immunohistochemical markers that have been studied for HSIL, and dVIN.
Biomarker Lesion(s)
studied
Location Molecular Functions*
p16 (CDKN2A) (Darragh et al., 2012; Lerma et al., 2002; Riethdorf
et al., 2004; Rakislova et al., 2018; Faber et al., 2017; Watkins
et al., 2019; Yang and Hart, 2020; Dong et al., 2015; Cheng
et al., 2015; Hoevenaars et al., 2008; Jeffreys et al., 2018)
HSIL, dVIN nucleus transcription regulator; DNA binding; NF-ĸß binding; p53 binding;
protein kinase binding; RNA binding; ubiquitin-protein ligase inhibitor
activity
p53 (Yang and Hart, 2020; Jeffreys et al., 2018; Wellenhofer and
Brustmann, 2012; Santos et al., 2004; Hantschmann et al.,
2005; Liegl and Regauer, 2006; Rolfe et al., 2003; Vanin et al.,
2002)
HSIL, dVIN nucleus transcription regulator; DNA binding; histone deacetylase regulator
activity; protein heterodimerization/homodimerization activity
CCND1 (Lerma et al., 2002; Rolfe et al., 2001) HSIL, dVIN nucleus transcription regulator; histone deacetylase binding; kinase activity
pRB (Lerma et al., 2002; Rolfe et al., 2001) HSIL nucleus sequence-specific DNA binding; transcription factor; ubiquitin protein
ligase binding
Ki-67/MIB-1 (van der Avoort et al., 2006; Hoevenaars et al., 2008) HSIL, dVIN nucleus ATP binding; nucleotide binding; protein binding
HDAC1 (Samartzis et al., 2011) HSIL nucleus transcription regulator; NF-kappaB binding; p53 binding
CTNNB1 (Li et al., 2013) HSIL, dVIN nucleus transcription regulator; cadherin binding; chromatin binding; SMAD
binding
CDH1 (Li et al., 2013) HSIL** plasma membrane alpha-catenin binding; beta-catenin binding; cell adhesion molecule
binding; cytoskeletal protein binding; gamma-catenin binding
SOX2 (Brustmann and Brunner, 2013) HSIL, dVIN nucleus transcription regulator
ƴ-H2AX (Brustmann et al., 2011) HSIL nucleus transcription regulator
Survivin (Brustmann et al., 2011; Wellenhofer and Brustmann,
2012)
HSIL cytoplasm chaperone binding; cofactor binding; cysteine-type endopeptidase
inhibitor activity involved in apoptotic process; enzyme binding;
protein heterodimerization / homodimerization activity; Ran GTPase
binding; tubulin binding
GATA3 (Goyal et al., 2018) HSIL, dVIN nucleus transcription regulator; HMG box domain binding; interleukin-2
receptor binding
MCM2 (Chen et al., 2010) HSIL nucleus enzyme - 3′-5′ DNA helicase activity; ATP binding; histone binding
TOP2A (Chen et al., 2010) HSIL nucleus enzyme - ATPase activity; histone deacetylase binding; ubiquitin
binding
hTERT (Wellenhofer and Brustmann, 2012) HSIL nucleus enzyme - nucleotidyltransferase activity; protein binding; tRNA binding
p-S6 (Pinto et al., 2013) HSIL, dVIN nucleus mRNA binding; protein binding; structural constituent of ribosome
STMN1 (Nooij et al., 2016) HSIL cytoplasm protein binding; tubulin binding
FSCN1 (Stewart and Crook, 2014) HSIL, dVIN cytoplasm actin binding; cadherin binding; RNA binding
CK17 (Podoll et al., 2016; Dasgupta et al., 2018) HSIL, dVIN cytoplasm MHC class II protein binding / receptor activity; structural constituent
of cytoskeleton
AKT1 (Ekeowa-Anderson et al., 2012) HSIL cytoplasm enzyme - kinase activity, transferase activity; calmodulin binding
MMP2 (Bovo et al., 2004) HSIL extracellular
space
enzyme - hydrolase activity, metalloendopeptidase activity
CK13 (Dasgupta et al., 2018) dVIN cytoplasm protein binding; structural molecule activity
ER (Zannoni et al., 2011) dVIN nucleus ligand-dependent receptor; DNA binding; transcription factor binding
PR (Zannoni et al., 2011) dVIN nucleus ligand-dependent receptor; DNA binding
* From IPA Gene View (QIAGEN).
** This marker was studied in dVIN, but the pattern of expression was same as that in the normal vulvar epithelium.
Fig. 3. High grade squamous intraepithelial lesion (HSIL), histology and p16 and p53 immunohistochemistry (IHC), original magnification 50X. A. Hematoxylin-
Eosin (HE) stained section shows the characteristic histology of HSIL. B. Block-like positivity can be appreciated on p16-IHC. C. On p53-IHC, scattered nuclear
staining in the suprabasal layers, with lack of staining in the basal layers is seen.
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(i) p53: On p53-IHC, HSIL usually shows wild-type (wt) staining,
characterized by sporadic nuclear staining, with weakly positive
to completely negative basal epithelial layer [Fig. 3]. In some
HSIL, ‘accentuated wt-p53’ pattern is seen, characterized by
weak, patchy staining in the basal layer, and a higher proportion
of positive nuclei in the suprabasal layers (Jeffreys et al., 2018).
(ii) Cyclin-D1 and pRB: Loss of pRB-expression in HSIL and VSCC
reflects disruption of pRB by HPV. The cyclinD1-CDK4 complex
reverses the tumor suppressor effect of pRB, and allows cell-cycle
progression. Normal vulvar epithelium is negative for cyclin-D1,
whereas its over-expression in both the nucleus and cytoplasm
has been reported in both HSIL and VSCC (Lerma et al., 2002;
Rolfe et al., 2001).
(iii) Histone deacetylases-class I (HDAC1): HDACs represses tran-
scription by increasing the affinity of histone complexes for DNA,
and also modifies the transcription factors p53, E2F, and pRB.
Increased nuclear expression of HDAC1,2, and 3 have been re-
ported for HSIL and VSCC (Samartzis et al., 2011).
(iv) E-Cadherin (CDH1)/ß-Catenin (CTNNB1): E-cadherin/ß-catenin
complex regulates cellular adhesion, proliferation, and survival.
Dysfunction of this complex has been implicated in carcinogen-
esis (Li et al., 2013). In non-neoplastic vulvar lesions, CDH1 and
ß-catenin are strongly expressed in the epithelial cell membranes
(Li et al., 2013). In HSIL, expression of both in the cytoplasm,
with or without expression in the cell membrane is seen (Li et al.,
2013).
(v) SRY-box 2 (SOX2): SOX2 controls pluripotency in both embryonic
and adult tissue-specific stem cells, and can induce pluripotency
in adult somatic cells (Brustmann and Brunner, 2013). Weak
nuclear SOX2-expression in the basal and parabasal epithelial
layers is seen in normal vulva. Increased, strong nuclear SOX2-
expression, particularly in the middle and upper-third of the
epithelium, has been reported for HSIL (Brustmann and Brunner,
2013).
(vi) H2A histone family member X (ƴ-H2AX): ƴ-H2AX is generated
from phosphorylation of the histone protein H2AX, in response to
DNA-double strand breaks. ƴ-H2AX induces chromatin mod-
ification, and apoptosis (Brustmann et al., 2011). Diffuse or
granular nuclear staining with ƴ-H2AX in all the epithelial layers
has been reported for HSIL (Brustmann et al., 2011).
(vii) GATA-binding protein 3 (GATA3): GATA3 is known to upregulate
the MDM2-proto-oncogene, which in turn downregulates and
degrades p53. Moderate to strong nuclear GATA3-expression in
non-neoplastic vulva, as well as in HSIL has been reported (Goyal
et al., 2018).
(viii) ProEx C: ProEx C is an antibody cocktail targeting the nuclear
enzymes minichromosome maintenance complex component 2
(MCM2), and topoisomerase IIa (TOP2A). MCM2 influences mi-
totic G1/S phase transition. TOP2A modulates chromosome
condensation and segregation, and is activated in response to
genotoxic stress. For HSIL, diffuse nuclear staining with ProEx C,
from lower one-third to full epithelial thickness, has been re-
ported. In normal vulvar epithelium, ProEx C only stains the basal
and parabasal layers (Chen et al., 2010).
(ix) Human Telomerase Reverse Transcriptase (hTERT): hTERT ex-
tends and maintains telomeres, and enables cells to overcome
replicative senescence. In HSIL, nuclear staining with hTERT
follows the distribution of atypical keratinocytes, being limited
to< 50% of the epithelial cells in most cases. hTERT staining
only in the basal/parabasal layers has been noted in normal
vulvar epithelium (Wellenhofer and Brustmann, 2012).
(x) Ki-67/MIB-1: Ki-67 is a nuclear antigen present in proliferating
human cells in all stages of the cell-cycle, except the G0 phase
(van der Avoort et al., 2006; Hoevenaars et al., 2008). MIB-1 is
the monoclonal antibody against Ki-67. In normal vulvar epi-
thelium, MIB-1 stains mainly the parabasal layers, and
infrequently the basal layers (Hoevenaars et al., 2008). In HSIL,
increased MIB-1 staining in both basal and parabasal layers, ex-
tending into the upper two-thirds of the epithelium can be seen
(van der Avoort et al., 2006; Hoevenaars et al., 2008).
(xi) Phosphorylated-S6 (p-S6): Hyperactivity of the EGFR/ERK, and
PI3K/AKT/mTOR signaling pathways, which are involved in SCC,
leads to phosphorylation of the ribosomal protein S6, which
modulates mRNA translation (Pinto et al., 2013). In normal
vulvar epithelium, the basal and suprabasal cells are negative for
p-S6, whereas in HSIL, the basal cells show nuclear p-S6-expres-
sion (Pinto et al., 2013).
3.2.4.2. Cytoplasmic markers
(i) Stathmin (STMN1): STMN1 is a microtubule-destabilising phos-
phoprotein, which regulates mitosis (Nooij et al., 2016). Normal
vulvar mucosa does not express STMN1, whereas in HSIL, cyto-
plasmic expression in more than one-third of the epithelial thick-
ness has been reported (Nooij et al., 2016).
(ii) Fascin-1 (FSCN1): FSCN1, an actin-bundling protein, promotes
migration and invasion of carcinoma cells. Increased cytoplasmic
FSCN1-expression in all epithelial layers, except in the surface
parakeratotic cells, has been reported for HSIL (Stewart and Crook,
2014). FSCN1 immunoreactivity is limited to the lower-third of the
epithelium in normal vulva.
(iii) Cytokeratin 17 (CK17): The intermediate filament protein CK17,
regulates protein synthesis and cell growth, and is expressed in
activated keratinocytes in the suprabasal layers of epidermis. In
HSIL, focal cytoplasmic CK17-staining of weak or moderate in-
tensity, in the superficial epithelial layers, has been reported
(Podoll et al., 2016).
(iv) Survivin: Apoptosis-inhibitor protein survivin is overexpressed in
human cancers, and is considered an unfavorable prognostic
marker (Brustmann et al., 2011; Wellenhofer and Brustmann,
2012). In normal vulva, survivin stains the cytoplasm of parabasal/
basal epithelial cells, whereas in HSIL, the staining pattern has
been reported to follow the extension of the atypical cells within
the epithelium (Wellenhofer and Brustmann, 2012).
(v) AKT1: AKT1 is a serine/threonine kinase, down-regulated by cu-
taneous HPV-types to weaken the keratin envelope and allow viral
release (Ekeowa-Anderson et al., 2012). AKT1 loss in HSIL corre-
lates with high copy numbers of episomal HPV16, i.e. is indicative
of early HPV-infection. Expression of AKT1 in HSIL correlates with
low copy numbers of episomal HPV16, and indicates HPV-in-
tegration (Ekeowa-Anderson et al., 2012).
3.2.4.3. Extracellular markers. Matrix metalloproteinase (MMP2):
MMP2, an enzyme of the metalloproteinase family, degrades type IV
collagen and fibronectin in the basement membrane, and facilitates
stromal and vascular invasion by tumor cells (Bovo et al., 2004).
Granular or diffuse cytoplasmic staining with MMP-2 in stromal cells
has been reported in HSIL and VSCC (Bovo et al., 2004).
3.2.5. Molecular markers
3.2.5.1. Allelic imbalances, loss of heterozygosity (LOH), copy number
alterations (CNA). Loss of chromosome (chr) 3p and gain of chr 3q has
been most frequently reported in HSIL and VSCC (Lin et al., 1998;
Flowers et al., 1999; Pinto et al., 1999; Rosenthal et al., 2001; Allen
et al., 2002; Bryndorf et al., 2004; Osakabe et al., 2007; Yangling et al.,
2007; Aulmann et al., 2008). LOH at chr 2.4 and chr 8.2 has been
identified in both HPV-related VSCC, and the adjacent HSIL (Lin et al.,
1998). Single studies have reported loss of chr 13q, and gain of chr 20p
and chr 20q for both HSIL and VSCC (Flowers et al., 1999; Bryndorf
et al., 2004). In addition, gain of chr 8q, and loss of chr 8p, chr 11, and
chr 17 in VSCC have been reported (Flowers et al., 1999; Pinto et al.,
1999; Rosenthal et al., 2001; Allen et al., 2002; Bryndorf et al., 2004;
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Yangling et al., 2007).
For HSIL that progressed to VSCC, Swarts et al. identified chr 1p, 1q,
3q, 20 gains and chr 4 loss (Swarts et al., 2018). Interestingly, in VSCC
samples with an adjacent HSIL, chr 1pq gains could be detected only in
the HSIL, and not in the VSCC, potentially implying intratumoral het-
erogeneity (Swarts et al., 2018). Swarts et al. also observed distinct
patterns of CNA in HSIL and dVIN, and that CNA were more frequent in
HSIL than in dVIN (Swarts et al., 2018).
3.2.5.2. Somatic mutations. Nooij et al. detected TP53 mutations in
both HSIL and VSCC, albeit in much lower frequency than in HPV-
independent counterparts (Nooij et al., 2017). Contrasting findings
were reported by Zięba et al., who detected TP53 mutations with
comparable frequency in HPV-related, and HPV-independent VSCC
(Zięba et al., 2018). They ascribed this difference to sequencing
techniques and the highly sensitive HPV-detection method used
(Zięba et al., 2018).
HRAS mutations have been detected in both HSIL and VSCC
(0–14%), whereas NOTCH1 mutations have been detected only in HSIL
(Nooij et al., 2017; Weberpals et al., 2017). Other mutations that have
been detected in HPV-related VSCC include PIK3CA (7–33%), CDKN2A
(0–25%), PTEN2 (9 %), FGFR3 (14 %), KIT (18 %), BRCA2 (17 %),
FBXW7 (3–17%) (Nooij et al., 2017; Zięba et al., 2018; Weberpals et al.,
2017; Han et al., 2018).
3.2.5.3. Microsatellite instability (MSI). Only a single study has reported
MSI for HPV-related VSCC (Lin et al., 1998).
3.2.5.4. Epigenetic changes. Hypermethylation of CDKN2A (9.1–15.4%),
Stratifin (45.5–53.8%), TSR1 (20 %), and TSLC1 (44.4 %), has been
reported for HSIL and VSCC, using methylation-specific PCR (ms-PCR)
(Gasco et al., 2002; Guerrero et al., 2011; O’Nions et al., 2001).
3.2.5.5. Expression profiling. Upregulation of genes involved in cell-
cycle regulation and proliferation, with the exception of cyclins D1 and
D2, has been reported for HSIL (Santegoets et al., 2007). Cyclins D1 and
D2 were significantly downregulated, probably due to the pronounced
upregulation of CDKN2A (Santegoets et al., 2007). Upregulation of
Fanconi genes (FANCA, FANCD2, and FANCE), and BRCA1 have been
reported in HSIL, which probably reflects the response to the HPV-
induced DNA damage. Downregulation of nuclear androgen and
estrogen receptors (AR and ESR1) potentially indicates reduced
paracrine and endocrine regulation (Santegoets et al., 2007). Cell-cell
adhesion molecules (ASAM, SLIT2, ITGA8, FN1, EPDR1) were also
downregulated in HSIL, indicating its tendency towards invasion
(Santegoets et al., 2007, 2012).
3.2.6. GEO DataSet analysis
Based on the expression levels of p16 (CDKN2A), 3 samples were
identified as HPV-related VSCC. In these samples, expression of 1117
probe sets (675 up and 442 down) differed significantly from the con-
trols. Of these, 342 probe sets (244 up and 98 down) were found to be
exclusively involved in HPV-related VSCC, i.e. not involved in HPV-
independent VSCC. The associated biological processes, canonical
pathways, and the upstream regulators of these differentially expressed
genes are discussed below.
3.2.6.1. Biological processes. The associated biological processes were
identified through Gene Ontology (GO) analysis using DAVID. Those
with the most significant p-values are depicted in Fig. 4. These included
processes related to host immune response to HPV-infection,
organismal injury and death, and proteolytic activity mediated by
proteasomes through ubiquitin-ligation.
3.2.6.2. Pathways. Based on the –log(p-values) of the differentially
expressed genes, the associated canonical pathways were identified
using IPA, and are depicted in Fig. 5. The protein ubiquitination
pathway was most significantly upregulated. This signaling pathway
helps degrade regulatory proteins involved in cell proliferation,
apoptosis, DNA repair, and antigen presentation. Several cancers are
known to manipulate the ubiquitin pathways to ensure tumor cell
survival and metastasis. Other significantly upregulated pathways i.e.
antigen presentation pathway, interferon signaling, and phagosome
maturation, regulate cellular immune response. The systemic lupus
erythematosus (SLE)-signaling pathway mediates aberrant activation of
T-cells, and is known to play a role in cellular growth and proliferation.
3.2.6.3. Upstream regulators. Based on the z-scores, 95 upstream
regulators (74 activated, 21 inhibited) were identified using IPA [Table
S2, supplementary document 2]. These comprised protein complexes,
cytokines, enzymes, G-protein coupled receptors, transmembrane
receptors, growth factors, ligand-dependent nuclear receptors, miRNAs,
transcription and translation regulators, and transporters. The top five
activated upstream regulators were the cytokines, tumor necrosis factor
(TNF), interferons gamma and alpha2 (IFNG, IFNA2) and prolactin
(PRL), and the transcription regulator, interferon regulatory factor 7
(IRF7). All of these are primarily associated with pro-inflammatory
functions, and host-response to viral infections.
3.3. HPV-independent VSCC precursors (dVIN)
3.3.1. Etiopathogenesis
HPV-independent VSCC has been associated with lichen sclerosus
(LS), and occasionally with LSC, although the exact mechanism of this
transformation remains unclear. The ‘scar cancer’ model has been
proposed as a possible explanation, where chronic inflammation leads
to repeated epithelial injury and incites malignant transformation
(Cohen et al., 2019).
Women with LS have a reported relative risk of 38.4 for the de-
velopment of dVIN and VSCC (Bigby et al., 2016). Long-standing LS,
and low compliance with high-dose potent topical steroid ointments
have been associated with higher rates of (pre)malignant transforma-
tion (Bigby et al., 2016).
The immune-microenvironment of LS resembles that of an auto-
immune disorder, characterized by a high concentration of CD8+, and
FOXP3+ T-cells, and T-cell receptor rearrangements; this probably
provides a fertile ground for carcinogenesis (Wenzel et al., 2007; Terlou
et al., 2012; Regauer et al., 2002).
TP53 mutations (missense, deletions, and nonsense) have been
identified in both dVIN and VSCC, and have therefore been implicated
in their pathogenesis (Hoang et al., 2016; Regauer et al., 2019). How-
ever, recent studies indicate that not all HPV-independent VSCC follow
the TP53 pathway, this will be discussed later.
3.3.2. Clinical features
Although more common amongst post-menopausal women of 60–80
years, dVIN has also been reported in women<40 years of age (Yang
and Hart, 2020). Clinically, dVIN often produces unifocal grey-white
discolorations with a roughened surface, and less frequently whitish
plaques, or nodules (Yang and Hart, 2020). The clitoris is frequently
involved. Perineal involvement is less common than in HSIL (Hinten
et al., 2018; McAlpine et al., 2017). Itching and burning sensations are
common presentations, but occasionally, dVIN can be asymptomatic
(Hoang et al., 2016).
dVIN is less frequently diagnosed as a stand-alone lesion, than ad-
jacent to VSCC. This has been attributed to under-diagnosis of dVIN,
due to its subtle histological appearance, and rapid progression to VSCC
(Eva et al., 2009). The median interval between biopsy of dVIN and
diagnosis of VSCC has been reported to be 43.5 months (range 8–102
months) (Bigby et al., 2016). VSCC arising in the background of dVIN
has poorer prognosis (overall survival and disease specific survival),
and recurs more commonly than VSCC associated with HSIL (Hinten
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et al., 2018; Eva et al., 2009). A history of prior, synchronous, or sub-
sequent VSCC can be present in upto 85.7 % of dVIN (Bigby et al.,
2016).
3.3.3. Histological features
Histological features of dVIN were extracted from 11 studies (Preti
et al., 2014; Hart, 2001; Hoang et al., 2016; Cohen et al., 2019; Yang
and Hart, 2020; Bigby et al., 2016; Reutter et al., 2016; van den Einden
et al., 2013; Dasgupta et al., 2018; Singh et al., 2015; Ordi et al., 2009).
The ‘differentiated’ appearance of dVIN results from premature kerati-
nization in the deeper epithelial layers, which is a consequence of
disturbed maturation [Fig. 6].. This overtly eosinophilic appearance
due to premature keratinization can be readily identified even under
low magnification (Hoang et al., 2016; Cohen et al., 2019). Unlike
HSIL, nuclear atypia in dVIN is often limited to the basal layers (Preti
et al., 2014; Hart, 2001; Yang and Hart, 2020).
The histological diagnosis of dVIN suffers from poor reproducibility
(van den Einden et al., 2013). A panel of experts from ISSVD con-
sensually accepted basal layer atypia as the only essential diagnostic
feature. Histological features arbitrated as ‘strongly supportive’ in-
cluded basal layer hyperchromasia, basal layer mitoses, and large
keratinocytes with abundant eosinophilic cytoplasm (Reutter et al.,
2016). Features of disturbed maturation, such as individual cell kera-
tinization, presence of squamous whorls and keratin pearls just above
the basal layer, and cobblestoning have been reported to be particularly
helpful for dVIN cases where nuclear atypia is difficult to discern (van
den Einden et al., 2013; Dasgupta et al., 2018). The histological features
are listed in Table 1.
dVIN can sometimes be hard to distinguish from the reactive
changes seen in LS, or LSC. Singh et al. therefore recommended that
biopsies should include the interface between the lesion and normal
skin, as this allows appreciation of the abrupt edges of dVIN, which
lichenoid lesions lack (Singh et al., 2015).
Infrequently, dVIN exhibits full thickness moderate to severe atypia,
similar to HSIL. These lesions are referred to as HSIL-like dVIN, or
dVIN-with basaloid morphology, [] and can be distinguished from HSIL
by the lack of koilocytes, and in certain cases, by the presence of focal
conventional dVIN-like areas (Ordi et al., 2009).
3.3.4. Immunohistochemical markers
Immunohistochemical markers studied in dVIN are presented
below, and summarized in Table 2. This information was extracted from
Fig. 4. Biological processes involved in HPV-related vulvar squamous cell carcinoma (VSCC).
DAVID GO enrichment analysis (biological process) of differentially expressed genes in HPV-related VSCC. The figure shows the most significant biological processes
(p<0.01) on the y-axis, and the fold enrichment on the x-axis. Asterisks indicate the p-values, *p< 0.01; **p< 0.001; ***p< 0.0001
Fig. 5. Canonical pathways involved in HPV-
related vulvar squamous cell carcinoma
(VSCC).
Left: The top 15 canonical pathways regulated
with statistical significance in HPV-related
VSCC are shown, along with comparative reg-
ulation of these pathways in HPV-independent
VSCC. Color-coding of the map corresponds to
the -log(p-value) of each canonical pathway,
calculated by Fisher's exact test, right-tailed.
Right: Color-coding corresponds to the z-
scores; red indicates predicted pathway acti-
vation, and black indicates that no predictions
were available
S. Dasgupta, et al. Critical Reviews in Oncology / Hematology 147 (2020) 102866
8
20 studies (van der Avoort et al., 2006; Yang and Hart, 2020;
Hoevenaars et al., 2008; Rolfe et al., 2001; Brustmann and Brunner,
2013; Goyal et al., 2018; Wellenhofer and Brustmann, 2012; Pinto
et al., 2013; Stewart and Crook, 2014; Podoll et al., 2016; Dasgupta
et al., 2018; Singh et al., 2015; Ordi et al., 2009; Santos et al., 2004;
Hantschmann et al., 2005; Liegl and Regauer, 2006; Rolfe et al., 2003;
Vanin et al., 2002; Jin and Liang, 2019; Zannoni et al., 2011). The
immunohistochemical markers have been categorized as per their sub-
cellular location as nuclear, or cytoplasmic. The biological processes
and canonical pathways associated with these markers are presented in
Table S1 (supplementary document 2).
3.3.4.1. Nuclear markers
(i) p53: The underlying TP53 mutations in dVIN can be reflected as
over-expression/mutation pattern, or null-pattern on p53-IHC (Yang
and Hart, 2000; Santos et al., 2004; Hantschmann et al., 2005). In
mutation pattern, p53-staining in> 90 % cells of the basal layer,
along with suprabasal extension, ranging from lower one-third to
full epithelial thickness is seen, and this is associated with missense
mutations [Fig. 7] (Santos et al., 2004; Hantschmann et al., 2005).
In null pattern on the other hand, complete negativity is noted. This
is seen in up to 27 % cases of dVIN, and is associated with nonsense
mutations (Singh et al., 2015).
A proportion of dVIN exhibits wild type (wt) p53-staining pattern
(Nooij et al., 2017). Further delineation of the histological and mole-
cular characteristics of these lesions is needed to determine whether
they represent a subset of dVIN, or a distinct category of precursor of
HPV-independent VSCC.
p53-IHC however, has limitations in distinguishing dVIN from li-
chenoid conditions. Increased p53-staining, named as ‘p53-wt over-
expression’ can be seen in 5–61% cases of LS, and up to 40 % cases of
squamous hyperplasia, due to oxidative stress (Santos et al., 2004;
Hantschmann et al., 2005; Liegl and Regauer, 2006; Rolfe et al., 2003;
Vanin et al., 2002). Moreover, p53-positivity has also been noted in
‘normal’-appearing vulvar skin, similar to the p53-signatures in the
fallopian tube and endometrium, the significance of which is yet un-
known (Jin and Liang, 2019).
(ii) p16: Complete negativity, to minimal focal staining with p16-IHC
has been reported for dVIN [Fig. 7] (Hoevenaars et al., 2008). For
dVIN histologically mimicking HSIL (HSIL-like dVIN), negative
p16-IHC, and mutation-pattern or null-pattern expression with
p53-IHC [Fig. 7] helps distinguish it from HSIL (Ordi et al., 2009).
(iii) Cyclin-D1: Nuclear cyclin-D1-expression has been reported to be
mildly increased in dVIN, compared to normal vulvar epithelium.
However, an almost identical staining pattern is seen in reactive
vulvar disorders (Rolfe et al., 2001).
(iv) SOX2: Increased, strong SOX2-staining in the nuclei of basal and
parabasal keratinocytes is seen in dVIN. In LS, only weak and
occasional SOX2-staining from the basal to the upper epithelial
layers is seen. SOX2-staining patterns in dVIN and LS have been
reported to differ significantly (p<0.0001) (Brustmann and
Brunner, 2013).
(v) GATA3: Partial to complete loss of nuclear expression of GATA3
in the basal layer, with or without loss in the parabasal layer has
been reported for dVIN (Goyal et al., 2018). Since strong GATA3-
staining has been noted in LS and LSC, GATA3 has been proposed
as a potential diagnostic adjunct for dVIN (Goyal et al., 2018).
(vi) hTERT: Nuclear staining with hTERT in dVIN has been reported
to follow the distribution of the atypical cells in the epithelium,
and to be significantly higher than that in LS (Wellenhofer and
Brustmann, 2012).
(vii) Estrogen and progesterone receptors (ERα, ERß, and PR): In dVIN
adjacent to VSCC in elderly patients, no nuclear expression of
ERα was seen, whereas in LS, ERα-expression in the middle and
lower-thirds of the epithelium was noted. For ERß, nuclear/cy-
toplasmic expression has been reported in both dVIN and LS.
Scant, nuclear PR-expression has been reported in normal vulvar
epithelium, LS, and dVIN (Zannoni et al., 2011).
(viii) Ki-67/MIB-1: Increased MIB-1-expression is seen in the basal and
parabasal layers in dVIN. This can be helpful in distinguishing
dVIN from LS, which usually shows only basal MIB-1-expression
(van der Avoort et al., 2006; Hoevenaars et al., 2008).
(ix) p-S6: Increased nuclear p-S6-expression in the basal/parabasal
layers, or extending across full epithelial thickness has been re-
ported for dVIN. In contrast, p-S6-expression in LS was reported
to be limited to the basal layers (Pinto et al., 2013).
3.3.4.2. Cytoplasmic markers
(i) FSCN1: Diffuse cytoplasmic FSCN1-staining has been reported for
dVIN, with some cases showing concurrent nuclear staining
(Stewart and Crook, 2014).
(ii) CK17: Intermediate to strong, diffuse, cytoplasmic CK17-expres-
sion, in the suprabasal layers to full epithelial thickness has been
reported in dVIN (Podoll et al., 2016). CK17-expression has been
reported to be significantly higher in dVIN compared to LS
(Dasgupta et al., 2018).
(iii) CK13: Weak cytoplasmic CK13-expression in the suprabasal or
superficial epithelial layers, or complete loss of CK13-expression
have been reported for dVIN (Dasgupta et al., 2018). For LS,
patchy/diffuse CK13-expression of moderate intensity, in the su-
prabasal layers of the epithelium has been reported (Dasgupta
et al., 2018).
Fig. 6. Differentiated vulvar intraepithelial neoplasia with characteristic his-
tological features; hematoxylin-eosin (HE) stain. A. A widened epithelium with
hyperkeratosis, parakeratosis, and an eosinophilic appearance can be appre-
ciated under low magnification (original magnification 25X). B. Nuclear atypia,
particularly prominent in the basal layers, can be appreciated under higher
magnification (original magnification 200X). Angulated nuclei (black arrow)
and mitotic figure (red arrow) are observed in the basal layer. Cobblestone
appearance, individual cell keratinisation, and macronucleoli are present (cir-
cled area) (For interpretation of the references to colour in this figure legend,
the reader is referred to the web version of this article).
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3.3.5. Molecular markers
A Allelic imbalances, LOH, CNA: Loss of chr 2.4, 5.2, 3p, 13q, and 17p
has been detected in both dVIN and HPV-independent VSCC (Lin
et al., 1998; Flowers et al., 1999). Loss of 3p and 17p has been most
frequently reported (Flowers et al., 1999; Pinto et al., 1999;
Rosenthal et al., 2001; Osakabe et al., 2007; Yangling et al., 2007;
Rolfe et al., 2003). Alterations in chr 8p23.1, 8p23.3, and 8p11.22,
and chr 3 and chr 8 isochromosome formation (3p/8p loss with 3q/
8q gain) have been more commonly detected in HPV-independent
VSCC than in HPV-related VSCC (Swarts et al., 2018). Gains in chr
8q, and losses in chr 1p, 3p, and 8p have been reported to be more
frequent in dVIN, than in HSIL (Swarts et al., 2018).
B Somatic mutations: Mutations of TP53 are the most frequent somatic
mutations in dVIN and HPV-independent VSCC (Brooks et al., 2000;
Trietsch et al., 2015). Frequency of TP53 mutations in VSCC, in
studies using next generation sequencing (NGS) or whole exome
sequencing (WES), varied between 41–79% (Nooij et al., 2017;
Zięba et al., 2018; Weberpals et al., 2017; Han et al., 2018; Watkins
et al., 2017). Other somatic mutations that have been detected in
VSCC, albeit in lower frequency, include HRAS (3–31%), NOTCH1
(28–41%), FGRF3 (4.8 %), CDKN2A (11–36%), FBXW7 (0–11%),
PIK3CA (0–19%), PPP2R1A (3 %), and EGFR (Cohen et al., 2019;
Nooij et al., 2017; Zięba et al., 2018; Weberpals et al., 2017; Han
et al., 2018). In lesions diagnosed histologically as dVIN, and
showing wt-p53 expression on IHC, Nooij et al. detected mutations
in NOTCH1 (20 % of cases) and HRAS (10 % of cases) (Nooij et al.,
2017).
C MSI: Bujko et al. could not detect MSI in HPV-independent VSCC,
while Pinto et al. detected MSI in 27 % of dVIN and 12 % of LS cases
in his study (Bujko et al., 2012; Pinto et al., 2000).
D Epigenetic changes: Hypermethylation of CDKN2A, Stratifin,
RASSF1A, RASSF2A, TSP-1, and MGMT have been reported for both
dVIN and VSCC on ms-PCR, with a higher frequency in VSCC, than
in dVIN (Gasco et al., 2002; Guerrero et al., 2011; Soufir et al.,
2007).
3.3.6. GEO DataSet analysis
Three samples from the included dataset were identified as HPV-
independent VSCC, in which the expression of 1158 probe sets (545 up
and 613 down) significantly differed from the control. Of these, 382
probe sets (203 up and 179 down) were exclusive for HPV-independent
VSCC. The associated biological processes, canonical pathways, and
upstream regulators were identified using DAVID, and IPA, and are
discussed below.
3.3.6.1. Biological processes. The upregulated biological processes with
the most significant p-values are depicted in Fig. 8. These included
biological processes associated with the transcription factor CREB,
metabolic processes, and reduced response to hormonal stimulation,
and cellular senescence.
3.3.6.2. Pathways. Based on the –log(p-values) of the differentially
expressed genes, the associated canonical pathways were identified,
and depicted in Fig. 9. Metabolic pathways known to play a role in cell
morphology, and embryonic development were most significantly
upregulated. This is probably a reflection of the metabolic re-
programming exhibited by solid tumors, to sustain proliferation and
survival. Aryl hydrocarbon receptor signaling was the only signaling
pathway in the top 5, which is known to down-regulate TGF-ß mediated
apoptosis.
3.3.6.3. Upstream regulators. Based on the z-scores, 57 upstream
regulators (13 activated, 44 inhibited) were identified [Table S3,
supplementary document 2]. Similarly to HPV-related VSCC, these
comprised protein complexes, cytokines, enzymes, growth factors, G-
protein coupled receptors, mature miRNAs, ligand-dependent nuclear
receptors, transcription and translation regulators, and transporters.
Fig. 7. Differentiated vulvar intraepithelial neoplasia (dVIN), histology and p53 and p16 immunohistochemistry (IHC), original magnification 50X.
A-C: dVIN with typical histology
A. Hematoxylin-Eosin (HE) stained section shows the characteristic histology of dVIN
B. On p53-IHC, mutation pattern staining, i.e. positive staining in the basal epithelial layers extending into the upper one-third of the epithelium is seen
C. Complete negativity is noted with p16-IHC
D-F: HSIL-like dVIN
D. HE stained section shows dVIN with full epithelial thickness atypia, which is more commonly noted in HSIL
E. Mutation pattern staining is noted with p53-IHC
F. Complete negativity is noted with p16-IHC
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The top five activated upstream regulators included 4 transcription
regulators i.e. MYCN proto-oncogene, NK2 homeobox 3 (NKX2-3), aryl
hydrocarbon receptor nuclear translocator (ARNT), and SOX2, and 1
mature microRNA (miR-125b-5p). MYCN, ARNT, and miR-125b-5p are
known to regulate TP53, while SOX2 is regulated by TP53.
3.4. HPV-independent VSCC precursors (others)
Atypical verruciform lesions, with histological appearance distinct
from dVIN, are other putative precursors of HPV-independent VSCC.
Their etiopathogenesis, rates of malignant transformation, and mole-
cular profiles remain largely unknown.
An example from this group is vulvar acanthosis with altered dif-
ferentiation (VAAD) (Nascimento et al., 2004). The typical histological
features of VAAD are acanthosis with variable verruciform architecture,
loss of granular layer with superficial epithelial pallor, and multi-
layered plaque-like parakeratosis (Nascimento et al., 2004).
Watkins et al. recently described a category of atypical verruciform
lesions, bearing PIK3CA and ARID2 mutations, instead of TP53 muta-
tions. These lesions, with an exophytic, acanthotic, or verruciform ar-
chitecture, and lacking the typical features of HSIL, or sufficient basal
atypia for a diagnosis of dVIN, were named ‘differentiated exophytic
vulvar intraepithelial lesion (DEVIL)’ (Watkins et al., 2017).
4. Discussion
Concepts of VSCC precursors have significantly evolved since the
first description in 1912, and a summary of current knowledge, with
emphasis on histology and biomarkers, is presented in this review. As
we included only English language literature, and articles with full-text
availability, some relevant information may have been missed. The
limited number of studies on immunohistochemical and molecular
markers of VSCC precursors, and the small sample sizes in most of
these, did not permit a meta-analysis. These are potential limitations of
this review. Nevertheless, we discuss the important insights into VSCC
and its precursors gained from the literature.
The WHO, ISSVD, and LAST committees have made commendable
efforts to introduce and advocate standardized terminology for VSCC
precursors. This allows better transfer of knowledge between clinicians,
pathologists, and patients, and also ensures reproducibility in research.
However, terminologies need modification in the face of newer in-
formation.
For dVIN, it is apparent that (i) malignant transformation is more
frequent than HSIL, and (ii) occasionally it exhibits the histology ty-
pically associated with HSIL. In view of these ‘high-grade’ features, the
legitimacy of the attribute ‘differentiated’ might be questioned. The
merit of using HPV-independent/HPV-negative HSIL/high-grade VIN,
in place of dVIN, may be deliberated.
Fig. 8. Biological processes involved in HPV-
independent vulvar squamous cell carcinoma
(VSCC).
DAVID GO enrichment analysis (biological
process) of differentially expressed genes in
HPV-independent VSCC. The figure shows the
most significant biological processes (p-
value< 0.01) on the y-axis, and fold enrich-
ment on the x-axis. Asterisks indicate
the p-values*, p<0.01; **p< 0.001;
***p< 0.0001
Fig. 9. Canonical pathways involved in HPV-
independent vulvar squamous cell carcinoma
(VSCC).
Left: The top 15 canonical pathways regulated
with statistical significance in HPV-in-
dependent VSCC are shown, along with com-
parative regulation of these pathways in HPV-
related VSCC. Color-coding of the map corre-
sponds to the -log(p-value) of each canonical
pathway, calculated by Fisher's exact test,
right-tailed.
Right: Color-coding corresponds to the z-
scores; red indicates predicted pathway acti-
vation, blue indicates predicted inhibition, and
black indicates that no predictions were avail-
able
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Since dVIN is known to develop in patients with chronic vulvar
dermatoses, biopsies should be performed for lesions recalcitrant to
therapy, or with a suspicious clinical appearance, to rule out dVIN.
Adequate sampling is also of utmost importance in these cases, as VSCC
is often diagnosed adjacent to dVIN (Preti et al., 2014).
Regarding HPV-independent VSCC and dVIN, several facets of the
pathogenesis still remain unknown. The association of LS and dVIN is
widely reported in the literature, but a history of LS is not universally
present in women with dVIN. Reports of p53-wt dVIN, and other pu-
tative precursors, e.g. DEVIL, indicate that HPV-independent VSCC and
its precursors constitute a heterogeneous category, with potentially
different pathogenesis and natural history.
The clinical, histological, and molecular characteristics of the newly
identified putative precursors need better delineation. Routine clinical
photographs of vulvar lesions suspected to be premalignant may be
useful in this context. One of the histological diagnostic criteria for
DEVIL, i.e. ‘insufficient basal atypia to warrant a diagnosis of dVIN’, can
be considered highly subjective. Furthermore, the malignant potential
of these lesions needs to be established through prospective studies.
As an ancillary tool for the histological diagnosis of dVIN and HSIL,
a reasonably wide assortment of immunohistochemical markers has
been evaluated. Nevertheless, p53 and p16-IHC remain the most widely
used in the clinical setting. Most studies on immunohistochemical
markers included small numbers, and rarely did more than one study
assess the same immunohistochemical marker. This has deterred their
translation to the clinics.
Since p53 has limited value in discriminating dVIN from lichenoid
lesions, immunohistochemical markers with higher specificity for dVIN,
especially based on genetic and epigenetic profile, need to be explored.
In view of the existence of cases of dVIN and HSIL with overlapping
histology, routine use of p16-IHC to aid their accurate categorization
should be considered, as the treatment and prognosis of both lesions
differ significantly. Routine use of p16-IHC, as a surrogate marker of
HPV-status, should also be considered for VSCC, as several studies have
demonstrated poorer survival and higher recurrence rates for HPV-in-
dependent VSCC.
Studies on molecular characterization of VIN are limited, but they
provide a few key findings. Intratumoral heterogeneity has been iden-
tified in HPV-related VSCC. For HPV-independent VSCC and precursors,
genotypic subtypes (p53-wt category) with distinct mutational profiles
have been identified. These data require validation in independent,
larger cohorts, using whole genome sequencing. Epigenetic alterations,
and the role of MSI are underexplored areas in VSCC, and may provide
useful information for diagnosis, or prognostication.
Our results from GEO analyses demonstrate the differences in
pathways involved in HPV-related, and HPV-independent VSCC.
Canonical pathways related to host-pathogen interactions were ex-
clusively upregulated in HPV-related VSCC, whereas metabolic path-
ways influenced by TP53 played a more significant role in HPV-in-
dependent VSCC. The categories of upstream regulators also differed;
pro-inflammatory cytokines were involved in HPV-related VSCC,
whereas transcription regulators related to TP53 were more operative
in HPV-independent VSCC. A limitation of our results is the small
sample size of the GEO dataset that was analyzed. Whether these pro-
cesses and pathways are similarly involved in the precursors of the
corresponding VSCC categories deserves exploration, as this may allow
identification of potential therapeutic targets to improve clinical man-
agement.
5. Conclusion
The category of HPV-independent VSCC and its precursors needs
better histological, immunohistochemical, and molecular delineation.
Combination of advanced sequencing techniques, and leverage of bio-
informatics can pave the path for molecular characterization of vulvar
(pre)malignancies, and personalized treatment.
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